A broadly neutralizing biparatopic Nanobody protects mice from lethal challenge with SARS-CoV-2 variants of concern

The ongoing COVID-19 pandemic and the frequent emergence of new SARS-CoV-2 variants of concern (VOCs), requires continued development of fast and effective therapeutics. Recently, we identified high-affinity neutralizing nanobodies (Nb) specific for the receptor-binding domain (RBD) of SARS-CoV-2, which are now being used as biparatopic Nbs (bipNbs) to investigate their potential as future drug candidates. Following detailed in vitro characterization, we chose NM1267 as the most promising candidate showing high affinity binding to several recently described SARS-CoV-2 VOCs and strong neutralizing capacity against a patient isolate of B.1.351 (Beta). To assess if bipNb NM1267 confers protection against SARS-CoV-2 infection in vivo, human ACE2 transgenic mice were treated by intranasal route before infection with a lethal dose of SARS-CoV-2. NM1267-treated mice showed significantly reduced disease progression, increased survival rates and secreted less infectious virus via their nostrils. Histopathological analyses and in situ hybridization further revealed a drastically reduced viral load and inflammatory response in lungs of NM1267-treated mice. These data suggest, that bipNb NM1267 is a broadly active and easily applicable drug candidate against a variety of emerging SARS-CoV-2 VOCs.

[1]  Toshiro Sato,et al.  Nasal delivery of single-domain antibody improves symptoms of SARS-CoV-2 infection in an animal model , 2021, PLoS pathogens.

[2]  D. Sheward,et al.  A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo , 2021, bioRxiv.

[3]  S. Yong.  Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments , 2021, Infectious diseases.

[4]  W. P. Duprex,et al.  Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses , 2021, Science Advances.

[5]  K. Schenke-Layland,et al.  NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies , 2021, EMBO reports.

[6]  R. Balicer,et al.  BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. Reply. , 2021, The New England journal of medicine.

[7]  B. Jewell.  Monitoring differences between the SARS-CoV-2 B.1.1.7 variant and other lineages , 2021, The Lancet Public Health.

[8]  A. Huppert,et al.  Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals , 2021, Nature Medicine.

[9]  Graham W. Taylor,et al.  Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Nature.

[10]  P. Maes,et al.  Drug development of an affinity enhanced, broadly neutralizing heavy chain-only antibody that restricts SARS-CoV-2 in rodents , 2021, bioRxiv.

[11]  S. Madhi,et al.  Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant , 2021, The New England Journal of Medicine.

[12]  K. Schenke-Layland,et al.  Immune response to SARS-CoV-2 variants of concern in vaccinated individuals , 2021, Nature Communications.

[13]  D. Ho,et al.  Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 , 2021, Nature.

[14]  Carl A. B. Pearson,et al.  Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Science.

[15]  T. Ganzenmüller,et al.  Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients , 2021, mSphere.

[16]  Wenbo Xu,et al.  SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape , 2021, Cell.

[17]  D. Stuart,et al.  Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera , 2021, Cell.

[18]  W. P. Duprex,et al.  Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses , 2021, bioRxiv.

[19]  H. Mouquet,et al.  Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies , 2021, Nature Medicine.

[20]  D. Fremont,et al.  SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies , 2021, Research square.

[21]  Naomi R. Waterlow,et al.  Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 , 2021, Nature.

[22]  A. Sigal,et al.  Sixteen novel lineages of SARS-CoV-2 in South Africa , 2021, Nature Medicine.

[23]  Wenbo Xu,et al.  No higher infectivity but immune escape of SARS-CoV-2 501Y.V2 variants , 2021, Cell.

[24]  Heshui Shi,et al.  Six-Month Follow-up Chest CT findings after Severe COVID-19 Pneumonia , 2021, Radiology.

[25]  John D. Davis,et al.  REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 , 2020, The New England journal of medicine.

[26]  D. Schneidman-Duhovny,et al.  Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2 , 2020, Science.

[27]  D. Skovronsky,et al.  SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 , 2020, The New England journal of medicine.

[28]  Shamus P. Keeler,et al.  SARS-CoV-2 infection of hACE2 transgenic mice causes severe lung inflammation and impaired function , 2020, Nature Immunology.

[29]  Megan Scudellari.  How the pandemic might play out in 2021 and beyond , 2020, Nature.

[30]  R. Owens,et al.  Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2 , 2020, Nature Structural & Molecular Biology.

[31]  V. Martel-Laferrière,et al.  Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals , 2020, mBio.

[32]  B. Strange,et al.  Temporal dynamics of amygdala response to emotion- and action-relevance , 2020, Scientific Reports.

[33]  Quanxin Long,et al.  Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections , 2020, Nature Medicine.

[34]  U. Rothbauer,et al.  A novel epitope tagging system to visualize and monitor antigens in live cells with chromobodies , 2020, Scientific Reports.

[35]  D. Sheward,et al.  An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction , 2020, Nature Communications.

[36]  X. Xie,et al.  Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells , 2020, Cell.

[37]  M. V. van Breemen,et al.  Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.

[38]  C. Hillyer,et al.  Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses , 2020, Trends in Immunology.

[39]  Q. Jin,et al.  Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain , 2020, Nature Communications.

[40]  Shinji Makino,et al.  An Infectious cDNA Clone of SARS-CoV-2 , 2020, Cell Host & Microbe.

[41]  N. Callewaert,et al.  Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies , 2020, Cell.

[42]  Lei Liu,et al.  Potent human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, bioRxiv.

[43]  J. Tang,et al.  Herd immunity – estimating the level required to halt the COVID-19 epidemics in affected countries , 2020, Journal of Infection.

[44]  R. Kulkarni.  Antibody-Dependent Enhancement of Viral Infections , 2019, Dynamics of Immune Activation in Viral Diseases.

[45]  R. Bruzzone,et al.  Fc receptors in antibody‐dependent enhancement of viral infections , 2015, Immunological reviews.

[46]  Serge Muyldermans,et al.  Nanobodies: natural single-domain antibodies. , 2013, Annual review of biochemistry.

[47]  David K. Meyerholz,et al.  Lethal Infection of K18-hACE2 Mice Infected with Severe Acute Respiratory Syndrome Coronavirus , 2006, Journal of Virology.

[48]  Jonathan L. Schmid-Burgk,et al.  COVID-19 Bibliometrics 8 th – 14 th February 2021 , 2021 .

[49]  K. Yoon,et al.  Antibody-dependent enhancement of virus infection and disease. , 2003, Viral immunology.

[50]  J. Ravetch.  Fc receptors. , 1997, Current opinion in immunology.